Does Tirzepatide Make You Tired? Trial Numbers, Eight Causes, the Timeline and What Actually Helps

Written by Nataliia Bondarchuk. Updated October 28, 2026.

Tirzepatide can make you tired, but the drug itself is rarely the direct cause. In the Zepbound trials, fatigue was reported by 5% of people on 5 mg, 6% on 10 mg and 7% on 15 mg, against 3% on placebo: a real effect, but a small one, and one the Mounjaro label does not list at all because it stayed below the reporting threshold in the diabetes trials. What most people experience as 'tirzepatide fatigue' is the consequence of what the drug does: eating a third less than before, drinking less without noticing, losing weight quickly, and, in people with diabetes who also take insulin or a sulfonylurea, blood sugar dipping lower than it used to. Each of those has a different fix, and a couple of them need a blood test rather than a nap. This guide gives the trial numbers, a cause-by-cause table with the tell-tale signs of each, the typical timeline, the practical changes that make the biggest difference, and the point at which tiredness on tirzepatide is a reason to call your prescriber.

The clearest numbers come from the Zepbound prescribing information, which pools the placebo-controlled weight-management trials. Fatigue was reported as an adverse event by 5%, 6% and 7% of people on 5, 10 and 15 mg respectively, against 3% on placebo, a pattern that rises gently with dose and sits far below the gut effects. Dizziness ran at 4 to 5% versus 2%, and hypotension at 1 to 2% versus 0%, both of which the label links to gut side effects and dehydration. In the Mounjaro diabetes trials fatigue did not reach the 5% threshold for listing. For comparison, the Wegovy label reports fatigue at 11% versus 5% on placebo, so semaglutide is, if anything, the more tiring of the two; the comparison between the drugs is in tirzepatide vs semaglutide.

Fatigue is a symptom with many parents, and tirzepatide creates several of them at once. The table lists the eight that account for almost every case, with the clue that points to each and the fix. Most people have two or three operating together, which is why 'drink more water' alone rarely solves it.

Tirzepatide's weight loss comes almost entirely from eating less: in SURMOUNT-1 people on 15 mg lost 20.9% of their body weight over 72 weeks, and the energy-expenditure studies show the drug does not burn calories, it removes the desire to eat them. The trouble is that appetite is also the signal most people use to decide when and how much to eat, and once it is switched off, intake can fall to a level that would be called a crash diet if it were deliberate. An adult who ate 2,400 calories a day and now eats 1,100 has cut by more than half, and tiredness, feeling cold, poor concentration and irritability are the predictable results. The fix is counter-intuitive: eat on a schedule, three meals a day, each built around 25 to 30 g of protein, whether or not you feel like it. People who do this lose the same amount of weight, because the drug's effect on total intake persists, but they lose it with their energy intact. Which foods make this easier and which make the gut effects worse is in best foods to eat on tirzepatide.

Fatigue follows the same arc as nausea, because it shares most of its causes. It appears in the first week of a new dose, is at its worst around days three to seven when the drug reaches peak levels, and fades over the following two to three weeks as the body adapts and eating settles into a new pattern. Because the standard escalation adds 2.5 mg every four weeks, people who climb the ladder on schedule can feel a tiredness cycle at each step for four to six months; those who pause a step when the previous one is still rough usually feel better overall and lose no ground. Once on a stable maintenance dose, the drug-related component disappears for nearly everyone, and what remains is diet, hydration or something unrelated. The week-by-week pattern of weight and side effects is in tirzepatide weight loss by week, and the dose steps in tirzepatide dosage.

On its own tirzepatide does not cause meaningful hypoglycemia: it stimulates insulin only when glucose is high, and in people without diabetes the rate of glucose under 54 mg/dL was 0.3%. Combined with insulin or a sulfonylurea (glipizide, glimepiride, glyburide) it is a different drug, because those medicines push insulin regardless of glucose and tirzepatide magnifies their effect; the diabetes trial recorded hypoglycemia in 4.2% versus 1.3% on placebo, with insulin users excluded, and the rate is higher when insulin is on board. Hypoglycemia feels like tiredness before it feels like anything else, and the giveaways are the company it keeps: trembling, sweating, sudden hunger, irritability, a racing heart, and relief within minutes of eating. Anyone on Mounjaro with insulin or a sulfonylurea who feels unusually tired should check a finger-stick glucose before assuming it is the drug, and the standard response is for the prescriber to lower the insulin or sulfonylurea dose when tirzepatide is started, not afterwards.

Three findings point away from tirzepatide. Fatigue that began before the drug, or that did not change when the dose did, is unlikely to be caused by it. Fatigue with specific companions, such as breathlessness on stairs, brittle nails and hair shedding (iron), pins and needles or a sore tongue (B12), feeling cold with constipation and dry skin (thyroid), or snoring with morning headaches (sleep apnea), has its own diagnosis. And fatigue that persists for more than a month at a stable dose with good hydration and adequate protein has, by definition, run past the point at which the drug's own effect fades. The practical test is a blood panel: full blood count, ferritin, B12, thyroid function, fasting glucose and electrolytes, which together catch the great majority of non-drug causes. Hair shedding alongside tiredness is common in month three to four and has its own explanation, covered in does tirzepatide cause hair loss.

Only indirectly. Fatigue tracks the calorie deficit, and the calorie deficit tracks weight loss, so people who feel tired in the first weeks are usually the people eating least. But the correlation is loose, plenty of people lose 20% with no fatigue at all, and the reverse inference is false: feeling fine does not mean the drug is failing. The useful measure is the scale over four-week blocks, not how you feel in week one. If the scale has stopped while fatigue persists, the two are often linked through the same cause, under-eating that has stalled metabolism, a pattern covered in why am I not losing weight on tirzepatide. How the dual GIP and GLP-1 action produces the appetite effect is in how Zepbound works.

Tiredness often follows the same pattern as the gut side effects, easing as each dose step settles; the timeline for each side effect is in how long Mounjaro side effects last.

Tirzepatide makes a small minority of people tired directly, 5 to 7% against 3% on placebo, and a much larger number tired indirectly, through under-eating, under-drinking, low blood sugar when combined with insulin, and the normal disruption of each dose step. Nearly all of it fades within a month of any dose change and nearly all of it responds to the same three measures: scheduled protein-led meals, two litres of fluid, and not rushing the escalation. Fatigue that outlasts those fixes is a reason for a blood test, not a reason to stop a drug that is otherwise working. Whether Mounjaro and Zepbound differ on any of this is answered in Mounjaro vs Zepbound: they do not, because they are the same tirzepatide.

This article summarizes the tirzepatide labels and published trials for general information. Persistent fatigue should be assessed by your prescriber.